Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Malignant Melanoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 68 articles: HTML format Text format

Single Articles

March 2010
1. MAIO M , Mackiewicz A, Testori A, Trefzer U, et al
   Large Randomized Study of Thymosin {alpha} 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
2. GUNTURU KS , Meehan KR, Mackenzie TA, Crocenzi TS, et al
   Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
3. VOIT C , Van Akkooi AC, Schafer-Hesterberg G, Schoengen A, et al
   Ultrasound Morphology Criteria Predict Metastatic Disease of the Sentinel Nodes in Patients With Melanoma.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. HAUSCHILD A , Weichenthal M, Rass K, Linse R, et al
   Efficacy of Low-Dose Interferon {alpha}2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of >= 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial.
   J Clin Oncol. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
5. SANTILLAN AA , Messina JL, Marzban SS, Crespo G, et al
   Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
6. JANKU F , Kurzrock R
   Adjuvant Interferon in High-Risk Melanoma: End of the Era?
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles   
   
   
   
7. O'DAY SJ , Atkins MB, Boasberg P, Wang HJ, et al
   Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. BALCH CM , Gershenwald JE, Soong SJ, Thompson JF, et al
   Final Version of 2009 AJCC Melanoma Staging and Classification.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. ALEXANDER HR JR , Fraker DL, Bartlett DL, Libutti SK, et al
   Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment Parameters.
   J Clin Oncol. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. GOULD ROTHBERG BE , Berger AJ, Molinaro AM, Subtil A, et al
    Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. SENZER NN , Kaufman HL, Amatruda T, Nemunaitis M, et al
    Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
12. O'DAY S , Gonzalez R, Lawson D, Weber R, et al
    A Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. BILIMORIA KY , Raval MV, Bentrem DJ, Wayne JD, et al
    National Assessment of Melanoma Care Using Formally Developed Quality Indicators.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
14. SANKI A , Uren RF, Moncrieff M, Tran KL, et al
    Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. NEWTON-BISHOP JA , Beswick S, Randerson-Moor J, Chang YM, et al
    Serum 25-Hydroxyvitamin D3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. VOIT CA , van Akkooi AC, Schafer-Hesterberg G, Schoengen A, et al
    Rotterdam Criteria for Sentinel Node (SN) Tumor Burden and the Accuracy of Ultrasound (US) -Guided Fine-Needle Aspiration Cytology (FNAC): Can US-Guided FNAC Replace SN Staging in Patients With Melanoma?
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
17. BASTIAANNET E , Wobbes T, Hoekstra OS, van der Jagt EJ, et al
    Prospective Comparison of [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Patients With Melanoma With Palpable Lymph Node Metastases: Diagnostic Accuracy and Impact on Treatment.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. GIMOTTY PA , Yoon F, Hammond R, Rosenbaum P, et al
    Therapeutic Effect of Sentinel Lymph Node Biopsy in Melanoma Remains an Open Question.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    July 2009
19. AGARWALA SS , Gray RJ, Wong MK
    Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    
20. MOHR P , Hauschild A, Trefzer U, Weichenthal M, et al
    Quality of Life in Patients Receiving High-Dose Interferon Alfa-2b After Resected High-Risk Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    June 2009
21. JENSEN TO , Schmidt H, Moller HJ, Hoyer M, et al
    Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. WALBERT T , Sloan AE, Cohen ML, Koubeissi MZ, et al
    Symptomatic neurocutaneous melanosis and Dandy-Walker malformation in an adult.
    J Clin Oncol. 2009;27:2886-7.
    PubMed     Text format     Related articles   
    
    
    
23. TRAN B , Fong C, Tong M, Hosking P, et al
    Malignant Melanoma Mimicking Acute Leukemia.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    
24. SABATINO M , Kim-Schulze S, Panelli MC, Stroncek D, et al
    Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.
    J Clin Oncol. 2009;27:2645-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
25. LENS M , Rosdahl I, Newton-Bishop J
    Cutaneous Melanoma During Pregnancy: Is the Controversy Over?
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    
26. LEE CC , Faries MB, Wanek LA, Morton DL, et al
    Improved Survival for Stage IV Melanoma From an Unknown Primary Site.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. BOTTOMLEY A , Coens C, Suciu S, Santinami M, et al
    Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. HAUSCHILD A , Weichenthal M, Rass K, Linse R, et al
    Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node-Negative Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. GLASPY J , Ribas A, Chmielowski B
    Interferon Alfa in the Postsurgical Management of High-Risk Melanoma: Is It Worth It?
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    April 2009
30. KIRKWOOD JM , Tarhini AA
    Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    
31. HAUSCHILD A , Agarwala SS, Trefzer U, Hogg D, et al
    Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. MCELEARNEY ST , Dengel LT, Robertson Vaughters AB, Patterson JW, et al
    Neonatal Congenital Malignant Melanoma With Lymph Node Metastasis.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    March 2009
33. FINDEISEN P , Zapatka M, Peccerella T, Matzk H, et al
    Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. BILIMORIA KY , Balch CM, Wayne JD, Chang DC, et al
    Health Care System and Socioeconomic Factors Associated With Variance in Use of Sentinel Lymph Node Biopsy for Melanoma in the United States.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
35. HOCEVAR M , Peric B, Besic N, Zgajnar J, et al
    Different Natural Course of Disease in Patients With Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles   
    
    
    
36. PECTASIDES D , Dafni U, Bafaloukos D, Skarlos D, et al
    Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. LOPEZ MN , Pereda C, Segal G, Munoz L, et al
    Prolonged Survival of Dendritic Cell-Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor {beta}-Expressing T Cells.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. CAMACHO LH , Antonia S, Sosman J, Kirkwood JM, et al
    Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma.
    J Clin Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
39. VAN AKKOOI AC , de Wilt JH, Verhoef C, Eggermont AM, et al
    The Rotterdam criteria for sentinel node tumor load: the simplest prognostic factor?
    J Clin Oncol. 2008;26:6011.
    PubMed     Text format     Related articles   
    
    
    
40. TARHINI AA , Stuckert J, Lee S, Sander C, et al
    Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
41. DAUD AI , Deconti RC, Andrews S, Urbas P, et al
    Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. WEBER JS , O'Day S, Urba W, Powderly J, et al
    Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. NEHLSEN-CANNARELLA SL
    "Groovy" Vaccine for Melanoma--But Which Groove?
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles   
    
    
    
44. ATKINS MB , Hsu J, Lee S, Cohen GI, et al
    Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordi
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. FONG L , Small EJ
    Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    J Clin Oncol. 2008;26:5275-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. VOIT CA , Schafer-Hesterberg G, Kron M, van Akkooi AC, et al
    Impact of Molecular Staging Methods in Primary Melanoma: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) of Ultrasound-Guided Aspirate of the Sentinel Node Does Not Improve Diagnostic Accuracy, But RT-PCR of Peripheral Blood Does Predict Surviva
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
47. SATO T , Eschelman DJ, Gonsalves CF, Terai M, et al
    Immunoembolization of Malignant Liver Tumors, Including Uveal Melanoma, Using Granulocyte-Macrophage Colony-Stimulating Factor.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
48. DUDLEY ME , Yang JC, Sherry R, Hughes MS, et al
    Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. SLINGLUFF CL JR , Petroni GR, Olson W, Czarkowski A, et al
    Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens.
    J Clin Oncol. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
50. ALEXANDRESCU DT , McClure R, Farzanmehr H, Dasanu CA, et al
    Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    J Clin Oncol. 2008;26:4047-8.
    PubMed     Text format     Related articles   
    
    
    July 2008
51. KIRKWOOD JM , Tarhini AA, Panelli MC, Moschos SJ, et al
    Next generation of immunotherapy for melanoma.
    J Clin Oncol. 2008;26:3445-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. GERSHENWALD JE , Andtbacka RH, Prieto VG, Johnson MM, et al
    Microscopic Tumor Burden in Sentinel Lymph Nodes Predicts Synchronous Nonsentinel Lymph Node Involvement in Patients With Melanoma.
    J Clin Oncol. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. DAUD AI , Mirza N, Lenox B, Andrews S, et al
    Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
    J Clin Oncol. 2008;26:3235-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
54. ZABIEROWSKI SE , Herlyn M
    Melanoma stem cells: the dark seed of melanoma.
    J Clin Oncol. 2008;26:2890-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2008
55. RIETSCHEL P , Wolchok JD, Krown S, Gerst S, et al
    Phase II study of extended-dose temozolomide in patients with melanoma.
    J Clin Oncol. 2008;26:2299-304.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. SOSMAN JA , Carrillo C, Urba WJ, Flaherty L, et al
    Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
    J Clin Oncol. 2008;26:2292-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. CHAPMAN PB
    Combining a peptide vaccine with high-dose interleukin-2.
    J Clin Oncol. 2008;26:2250-1.
    PubMed     Text format     Related articles   
    
    
    
58. MCDERMOTT DF , Sosman JA, Gonzalez R, Hodi FS, et al
    Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    J Clin Oncol. 2008;26:2178-85.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. BLANCHARD CM , Courneya KS, Stein K
    Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II.
    J Clin Oncol. 2008;26:2198-204.
    PubMed     Text format     Related articles    Abstract available
    
    
    
60. ADJEI AA , Cohen RB, Franklin W, Morris C, et al
    Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    J Clin Oncol. 2008;26:2139-46.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2008
61. HODI FS , Friedlander P, Corless CL, Heinrich MC, et al
    Major response to imatinib mesylate in KIT-mutated melanoma.
    J Clin Oncol. 2008;26:2046-51.
    PubMed     Text format     Related articles   
    
    
    
62. PALKA KT , Lebow RL, Weaver KD, Kressin MK, et al
    Intracranial collision metastases of small-cell lung cancer and malignant melanoma.
    J Clin Oncol. 2008;26:2042-6.
    PubMed     Text format     Related articles   
    
    
    March 2008
63. THOMPSON JA , Curti BD, Redman BG, Bhatia S, et al
    Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma.
    J Clin Oncol. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
64. TESTORI A , Richards J, Whitman E, Mann GB, et al
    Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
    J Clin Oncol. 2008;26:955-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. LEE CC , Faries MB, Wanek LA, Morton DL, et al
    Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
    J Clin Oncol. 2008;26:535-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. KORN EL , Liu PY, Lee SJ, Chapman JA, et al
    Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
    J Clin Oncol. 2008;26:527-34.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. GIMOTTY PA , Guerry D, Flaherty K
    Using benchmarks based on historical survival rates for screening new therapies for stage IV melanoma patients.
    J Clin Oncol. 2008;26:517-8.
    PubMed     Text format     Related articles   
    
    
    January 2008
68. BALCH CM , Soong SJ
    Predicting outcomes in metastatic melanoma.
    J Clin Oncol. 2008;26:168-9.
    PubMed     Text format     Related articles   
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: